<DOC>
	<DOCNO>NCT00880269</DOCNO>
	<brief_summary>This study evaluate efficacy safety single agent oral panobinostat patient refractory de novo refractory secondary AML .</brief_summary>
	<brief_title>Efficacy Safety Panobinostat ( LBH589 ) Patients With Refractory de Novo Secondary Acute Myelogenous Leukemia ( AML )</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Panobinostat</mesh_term>
	<criteria>Written inform consent prior studyspecific screening procedure Life expectancy ≥ 60 day Eastern Cooperative Group ( ECOG ) performance status ≤ 2 Refractory AML confirm initial diagnosis de novo AML ( exclude APL ) OR Refractory AML confirm initial diagnosis AML ( exclude APL ) secondary AHD MDS either condition precedent AML ( MDS/AHD ) Negative serum pregnancy test ( within 7 day first dose ) Negative urine pregnancy test immediately prior first dose Known HIV Psychiatric disorder interfere ability understand study give inform consent , and/or would impact study participation followup Concurrent use medication might prolong QT interval induce Torsade de Pointes Female patient pregnant breastfeed patient childbearing potential willing use double barrier method contraception study 3 month follow last dose study drug . Male patient whose sexual partner ( ) woman childbearing potential willing use double method contraception , one include condom , study 3 month end treatment Patient unable swallow capsule Patients impaired gastrointestinal system might cause interference digest absorb panobinostat Other Protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Acute myeloid leukemia</keyword>
	<keyword>AML</keyword>
	<keyword>relapse acute myeloid leukemia</keyword>
	<keyword>refractory AML</keyword>
	<keyword>refractory de novo AML</keyword>
	<keyword>refractory secondary AML</keyword>
	<keyword>secondary AML</keyword>
	<keyword>AML follow myelodysplastic syndrome ( MDS )</keyword>
	<keyword>AML follow antecedent hematological disorder ( AHD )</keyword>
	<keyword>AML resistant therapy</keyword>
</DOC>